AstraZeneca PLC banner

AstraZeneca PLC
OTC:AZNCF

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
OTC:AZNCF
Watchlist
Price: 204.27 USD 1.72% Market Closed
Market Cap: $316.7B

Wall St Price Targets

AZNCF Price Targets Summary
AstraZeneca PLC

Wall Street analysts forecast AZNCF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AZNCF is 242.3 USD with a low forecast of 165.34 USD and a high forecast of 282.94 USD.

Lowest Forecast
Price Target
165.34 USD
19% Downside
Average Forecast
Price Target
242.3 USD
19% Upside
Highest Forecast
Price Target
282.94 USD
39% Upside
AstraZeneca PLC Competitors:
Price Targets
CCOI
Cogent Communications Holdings Inc
67% Upside
JNJ
Johnson & Johnson
2% Upside
GFS
Globalfoundries Inc
1% Upside

Revenue
Forecast

6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 8%.

Gross Profit
Forecast

6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
6% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 8%.

Operating Income
Forecast

4% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss
4% / Year
Past Growth
21% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 3 years is 21%.

Pre-Tax Income
Forecast

4% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-50%
Average Miss
4% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-50%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 26%.

Net Income
Forecast

4% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-49%
Average Miss
4% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
-49%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 3 years is 26%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is AZNCF's stock price target?
Price Target
242.3 USD

According to Wall Street analysts, the average 1-year price target for AZNCF is 242.3 USD with a low forecast of 165.34 USD and a high forecast of 282.94 USD.

What is the Revenue forecast for AstraZeneca PLC?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 3 years is 8%.

What is the Gross Profit forecast for AstraZeneca PLC?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 3 years is 8%.

What is the Operating Income forecast for AstraZeneca PLC?
Projected CAGR
21%

Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 3 years is 21%.

What is the Pre-Tax Income forecast for AstraZeneca PLC?
Projected CAGR
26%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 26%.

What is the Net Income forecast for AstraZeneca PLC?
Projected CAGR
26%

Over the last 13 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 3 years is 26%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett